NYSE:LLYPharmaceuticals
How Eli Lilly’s US$3.5 Billion Obesity Plant Investment At Eli Lilly (LLY) Has Changed Its Investment Story
Eli Lilly has announced plans to invest more than US$3.50 billion in a new injectable-medicine manufacturing facility in Pennsylvania’s Lehigh Valley, dedicated to next-generation weight-loss therapies such as the investigational retatrutide.
This plant, Lilly’s fourth new U.S. site since 2025, highlights how the group is pairing AI-enabled manufacturing with a large domestic expansion program exceeding US$50.00 billion in capital commitments to support its obesity portfolio.
With this...